Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
November 15, 2024 13:15 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
November 01, 2024 09:17 ET
|
Spherix Global Insights
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
October 09, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Renown Welcomes the First Transplant Nephrologist to Region & Announces Renown Transplant Institute
October 03, 2024 17:26 ET
|
Renown Health
Reno, NEV., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Renown Health is pleased to announce the appointment of Narisorn Atsava-Svate, MD, a distinguished transplant nephrologist. With over 18 years of...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
September 03, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 07:10 ET
|
Unicycive Therapeutics, Inc.
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company”...
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
July 17, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 11, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
July 10, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE...